Back to Search
GITASREE BORTHAKUR, M.D.
M.D.
Diagnostic Radiology Physician
NPI: 1891054656IndividualAccepts Medicare
Specialties, Licenses & Credentials
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
A148478(CA)
CMS Specialties
PrimaryDIAGNOSTIC RADIOLOGY
Education
NORTHEASTERN OHIO UNIVERSITY COLLEGE OF MEDICINE
Class of 2012
Research & Publications (20)
Exfoliated buccal mucosa cells as a source of DNA to study oxidative stress.
PMID 18199726·Cancer Epidemiol Biomarkers Prev·2008
2-rct
Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood.
PMID 12871332·J Thromb Haemost·2003
8-other
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
PMID 19517462·Cancer·2009
8-other
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
PMID 19441109·Cancer·2009
8-other
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
PMID 19517473·Cancer·2009
3-trial
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
PMID 19652057·J Clin Oncol·2009
3-trial
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
PMID 19369233·Blood·2009
8-other
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
PMID 19531657·Blood·2009
8-other
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
PMID 19282457·Blood·2009
3-trial
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
PMID 19402171·Cancer·2009
8-other
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
PMID 19242494·Leukemia·2009
3-trial
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
PMID 18932257·Cancer·2008
3-trial
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.
PMID 18955453·J Clin Oncol·2008
4-observational
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
PMID 18519513·Haematologica·2008
8-other
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
PMID 18565853·Blood·2008
2-rct
Challenges in surgical management of abdominal pain in the neutropenic cancer patient.
PMID 18580213·Ann Surg·2008
8-other
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
PMID 18846563·Cancer·2008
8-other
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
PMID 19088047·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9998 CROSSPOINT BLVD, STE 200
INDIANAPOLIS, IN 46256 - Phone
- (317) 806-8260
Quick Facts
- NPI
- 1891054656
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile